STING1 and cancer: This upregulation of IFNβ1 after treatment with cytotoxic agents goes in line with previous studies that have shown that high levels of damage in cancer cells after treatment results in the activation of the STING/IRF3 pathway and drives IFNβ1 expression [177,178,179].